Comments on: Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb’s PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma

Comments on: Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb’s PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma https://www.worldpharmatoday.com/press-releases/phase-iii-opdivo-nivolumab-trial-shows-bristol-myers-squibbs-pd-1-immune-checkpoint-inhibitor-is-first-to-demonstrate-anti-tumor-activity-in-patients-with-hepatocellular-carcinoma/ Magazine for the C-level Pharma Executives Thu, 28 May 2015 18:30:00 +0000 hourly 1 https://wordpress.org/?v=6.9.4